middle.news
Telix adds Pixclara momentum to strong Q3 growth and ITM merger
8:36am on Wednesday 21st of October, 2026 AEDT
•
Healthcare
Read Story
Telix adds Pixclara momentum to strong Q3 growth and ITM merger
8:36am on Wednesday 21st of October, 2026 AEDT
Key Points
Q3 group revenue rose 19% to US$245 million
Precision Medicine revenue increased 30% to US$201 million
Pixclara received FDA approval and first commercial doses were administered
Proposed US$1.65 billion ITM merger remains subject to shareholder approval
Read Story
middle.
Tap to Read
Tap the card to read the full analysis
about
Telix Pharmaceuticals (ASX:TLX)
OPEN ARTICLE